{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T13:28:56Z","timestamp":1774618136415,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      In 2020, the World Health Organization declared SARS-CoV-2 a global public health emergency. Healthcare systems were forced to reorganize care delivery and implement wide-ranging infection control strategies. Among hospital-acquired infections, toxin-producing\n                      <jats:italic>Clostridioides difficile<\/jats:italic>\n                      infection remains a major concern due to its transmission via contact and its association with high morbidity and mortality. Although primarily aimed at preventing viral transmission, the measures introduced during the COVID-19 pandemic may have influenced the incidence of other nosocomial infections, including toxin-producing\n                      <jats:italic>Clostridioides difficile<\/jats:italic>\n                      infection.\n                    <\/jats:p>\n                    <jats:p>\n                      This study aimed to evaluate and compare the incidence of nosocomial toxin-producing\n                      <jats:italic>Clostridioides difficile<\/jats:italic>\n                      infection during the pandemic and pre-pandemic periods, and to confirm associated risk factors across both periods.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective observational cohort study at A Coru\u00f1a University Hospital, including data from 2017 to 2022. Patients meeting criteria for nosocomial\n                      <jats:italic>Clostridioides difficile<\/jats:italic>\n                      infection were categorized into pre-pandemic (2017-2019) or pandemic (2020-2022) cohorts. Variables analyzed included demographics (age, sex), prior antibiotic use, antiulcer therapy, immunosuppression and surgical history. Incidence rates were calculated and compared between periods, and associations between risk factors and toxin-producing\n                      <jats:italic>Clostridioides difficile<\/jats:italic>\n                      infection were analyzed using odds ratios (OR).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 249 nosocomial toxin-producing\n                      <jats:italic>Clostridioides difficile<\/jats:italic>\n                      infection cases were identified: 89 pre-pandemic and 160 during the pandemic, reflecting a 79.8% increase. Patients hospitalized during the pandemic faced a 92% greater risk of toxin-producing\n                      <jats:italic>Clostridioides difficile<\/jats:italic>\n                      infection (RR=1.92; CI95%: 1.48-2.49;\n                      <jats:italic>P<\/jats:italic>\n                      =0.001). Established risk factors such as prior antibiotic exposure (80% during the pandemic vs 86.5% pre-pandemic;\n                      <jats:italic>P<\/jats:italic>\n                      =0.20) and immunosuppression was frequent (39.3% pre-pandemic; 46.9% pandemic;\n                      <jats:italic>P<\/jats:italic>\n                      =0.25).\n                    <\/jats:p>\n                    <jats:p>\n                      Notably, the use of proton pump inhibitors significantly increased during the pandemic (\n                      <jats:italic>P<\/jats:italic>\n                      =0.02; 95%CI: 0.02\u20130.36). Surgical history, particularly gastrointestinal surgery, was significantly associated with complications (OR=6.6, 95%CI: 2.18-20.18). The incidence density of toxin-producing\n                      <jats:italic>Clostridioides difficile<\/jats:italic>\n                      infection (TCDI) during the pandemic years was\u00a01.44 TCDI\/10,000 patient-days. Predisposing factors included solid organ neoplasms (pre-pandemic 33.7%; pandemic 33.1%;\n                      <jats:italic>P<\/jats:italic>\n                      =0.36), secondary immunosuppression (pre-pandemic 31.5%; pandemic 40.6%;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.41).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Patients admitted experienced a significantly higher risk of acquiring toxin-producing\n                      <jats:italic>Clostridioides difficile<\/jats:italic>\n                      infection during the pandemic. The data also indicate an increase in mortality associated with this infection and highlight proton pump inhibitor use as a contributing factor to the higher incidence.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13690-026-01859-6","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T20:04:17Z","timestamp":1771617857000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence of hospital-acquired toxin-producing clostridioides difficile infection between the pre-pandemic (2017\u20132019) and pandemic (2020\u20132022): a retrospective cohort study"],"prefix":"10.1186","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3148-3573","authenticated-orcid":false,"given":"Raquel Garc\u00eda","family":"Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9 Pereira","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandra Pilar Garc\u00eda","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabi\u00e1n Freijedo","family":"Fari\u00f1as","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela Nogueira","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"1859_CR1","unstructured":"Gobierno de Espa\u00f1a. Real Decreto 463\/2020, de 14 de marzo, por el que se declara el estado de alarma para la gesti\u00f3n de la situaci\u00f3n de crisis sanitaria ocasionada por el COVID-19. Bolet\u00edn Oficial del Estado. 2020. Available from: https:\/\/www.boe.es\/boe\/dias\/2020\/03\/14\/pdfs\/BOE-A-2020-3692.pdf. [cited 2025 May 25]."},{"key":"1859_CR2","unstructured":"World Health Organization. WHO Director-General\u2019s opening remarks at the media briefing on COVID-19\u201311 March 2020. 2020. Available from: https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. [cited 2025 May 25]."},{"key":"1859_CR3","unstructured":"Centers for Disease Control and Prevention. Infection Control Guidance: COVID-19. Available from: https:\/\/www.cdc.gov\/covid\/hcp\/infection-control\/index.html. [cited 2025 May 11]."},{"key":"1859_CR4","doi-asserted-by":"publisher","unstructured":"Arnold L, Bimczok S, Sch\u00fctt H, Lisak-Wahl S, Buchberger B, Stratil JM. How to protect long-term care facilities from pandemic-like events? A systematic review on the effectiveness of non-pharmacological measures to prevent viral respiratory infections. BMC Infect Dis. 2024;24(1):589. Available from: https:\/\/bmcinfectdis.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s12879-024-09271-7. [cited 2025 May 19].","DOI":"10.1186\/s12879-024-09271-7"},{"key":"1859_CR5","unstructured":"World Health Organization. Transmission of SARS-CoV-2: implications for infection prevention precautions. Available from: https:\/\/www.who.int\/news-room\/commentaries\/detail\/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions. [cited 2025 May 11]."},{"key":"1859_CR6","doi-asserted-by":"crossref","unstructured":"Cojocariu C, Girleanu I, Trifan A, Olteanu A, Muzica CM, Huiban L et al. Did the SARS-CoV-2 pandemic cause an endemic Clostridium difficile infection? World J Clin Cases. 2021;9(33):10180\u20138. Available from: https:\/\/www.wjgnet.com\/2307-8960\/full\/v9\/i33\/10180.htm. [cited 2024 Jul 22].","DOI":"10.12998\/wjcc.v9.i33.10180"},{"key":"1859_CR7","doi-asserted-by":"crossref","unstructured":"Aho Glele LS, De Rougemont A. Non-pharmacological strategies and interventions for effective COVID-19 control: a narrative review. J Clin Med. 2023;12(20):6465. Available from: https:\/\/www.mdpi.com\/2077-0383\/12\/20\/6465. [cited 2025 May 19].","DOI":"10.3390\/jcm12206465"},{"key":"1859_CR8","doi-asserted-by":"crossref","unstructured":"Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by SHEA and IDSA. Infect Control Hosp Epidemiol. 2010;31(5):431\u201355. Available from: https:\/\/www.cambridge.org\/core\/product\/identifier\/S0195941700029064\/type\/journal_article. [cited 2024 Jul 28].","DOI":"10.1086\/651706"},{"key":"1859_CR9","volume-title":"Protocolo de vigilancia y control de microorganismos multirresistentes o de especial relevancia cl\u00ednico-epidemiol\u00f3gica","author":"Red Nacional de Vigilancia Epidemiol\u00f3gica","year":"2016","unstructured":"Red Nacional de Vigilancia Epidemiol\u00f3gica. Protocolo de vigilancia y control de microorganismos multirresistentes o de especial relevancia cl\u00ednico-epidemiol\u00f3gica. Madrid: RENAVE; 2016."},{"key":"1859_CR10","doi-asserted-by":"crossref","unstructured":"Ponce-Alonso M, S\u00e1ez de la Fuente J, Rinc\u00f3n-Carlavilla A, Moreno-N\u00fa\u00f1ez P, Mart\u00ednez-Garc\u00eda L, Escudero-S\u00e1nchez R et al. Impact of COVID-19 pandemic on nosocomial Clostridioides difficile infection. Infect Control Hosp Epidemiol. 2021;42(4):406\u201310. Available from: https:\/\/www.cambridge.org\/core\/product\/identifier\/S0899823X20004547\/type\/journal_article. [cited 2024 Jul 29].","DOI":"10.1017\/ice.2020.454"},{"key":"1859_CR11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2217\/fmb-2020-0275","volume":"16","author":"S Khanna","year":"2021","unstructured":"Khanna S, Kraft CS. The interplay of SARS-CoV-2 and Clostridioides difficile infection. Future Microbiol. 2021;16:439\u201343. https:\/\/doi.org\/10.2217\/fmb-2020-0275.","journal-title":"Future Microbiol"},{"key":"1859_CR12","doi-asserted-by":"crossref","unstructured":"O\u2019Toole PW, Jeffery IB. Microbiome\u2013health interactions in older people. Cell Mol Life Sci. 2018;75(1):119\u201328. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11105677\/. [cited 2025 Nov 30].","DOI":"10.1007\/s00018-017-2673-z"},{"key":"1859_CR13","doi-asserted-by":"crossref","unstructured":"Bloomfield MG, Carmichael AJ, Gkrania-Klotsas E. Mortality in Clostridium difficile infection: a prospective analysis of risk predictors. Eur J Gastroenterol Hepatol. 2013;25(6):700\u20135. Available from: http:\/\/journals.lww.com\/00042737-201306000-00010. [cited 2024 Jul 25].","DOI":"10.1097\/MEG.0b013e32835ed64d"},{"issue":"9","key":"1859_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005665","volume":"4","author":"M Takahashi","year":"2014","unstructured":"Takahashi M, Mori N, Bito S. Multi-institution case\u2013control and cohort study of risk factors for development and mortality of Clostridium difficile infections in Japan. BMJ Open. 2014;4(9):e005665.","journal-title":"BMJ Open"},{"issue":"2","key":"1859_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.cmi.2014.08.017","volume":"21","author":"MA Olsen","year":"2015","unstructured":"Olsen MA, Yan Y, Reske KA, Zilberberg MD, Dubberke ER. Recurrent Clostridium difficile infection is associated with increased mortality. Clin Microbiol Infect. 2015;21(2):164\u201370.","journal-title":"Clin Microbiol Infect"},{"key":"1859_CR16","doi-asserted-by":"publisher","unstructured":"Laszkowska M, Kim J, Faye AS, Joelson AM, Ingram M, Truong H et al. Prevalence of Clostridioides difficile and other gastrointestinal pathogens in COVID-19 patients. Dig Dis Sci. 2021;66(12):4398\u2013405. Available from: https:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s10620-020-06760-y. [cited 2024 Jul 25].","DOI":"10.1007\/s10620-020-06760-y"},{"key":"1859_CR17","doi-asserted-by":"crossref","unstructured":"Reacher M, Verlander NQ, Roddick I, Trundle C, Brown N, Farrington M et al. Excess mortality attributable to Clostridium difficile infection in an historic cohort. PLoS One. 2016;11(3):e0149983. Available from: https:\/\/dx.plos.org\/10.1371\/journal.pone.0149983. [cited 2024 Jul 25].","DOI":"10.1371\/journal.pone.0149983"},{"issue":"4","key":"1859_CR18","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.idc.2021.07.009","volume":"35","author":"A Krishna","year":"2021","unstructured":"Krishna A, Chopra T. Prevention of clostridium (Clostridioides) difficile infection. Infect Dis Clin North Am. 2021;35(4):995\u20131011.","journal-title":"Infect Dis Clin North Am"},{"key":"1859_CR19","doi-asserted-by":"crossref","unstructured":"Reveles KR, Frei AL, Strey KA, Young EH. Prevalence and outcomes of Clostridioides difficile infection during COVID-19 in US hospitals. Open Forum Infect Dis. 2022;9(9):ofac441. Available from: https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofac441\/6675656. [cited 2025 May 24].","DOI":"10.1093\/ofid\/ofac441"},{"key":"1859_CR20","doi-asserted-by":"crossref","unstructured":"Zouridis S, Sangha M, Feustel P, Richter S. Clostridium difficile infection rates during the COVID-19 pandemic in New York. Cureus. 2023;15(4):e37576. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10183223\/. [cited 2025 Dec 7].","DOI":"10.7759\/cureus.37576"},{"key":"1859_CR21","doi-asserted-by":"crossref","unstructured":"Wright LM, Skinner AM, Cheknis A, McBurney C, Ge L, Pacheco SM et al. Effect of COVID-19 on Clostridioides difficile infection in a VA hospital. Antibiotics. 2023;12(7):1159. Available from: https:\/\/www.mdpi.com\/2079-6382\/12\/7\/1159. [cited 2025 May 25].","DOI":"10.3390\/antibiotics12071159"},{"key":"1859_CR22","unstructured":"Servizo Galego de Sa\u00fade. \u00c1rea Sanitaria Coru\u00f1a-Cee 2022. Informe anual. Santiago de Compostela: SERGAS. 2022. Available from: https:\/\/xxicoruna.sergas.gal\/DAnosaorganizacion\/865\/AREA_SANITARIA_CORUN%cc%83A_CEE_2022.pdf. [cited 2025 Dec 1]."},{"issue":"9","key":"1859_CR23","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3109\/00365529709011203","volume":"32","author":"SJ Lewis","year":"1997","unstructured":"Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32(9):920\u20134. https:\/\/doi.org\/10.3109\/00365529709011203.","journal-title":"Scand J Gastroenterol"},{"issue":"Suppl 4","key":"1859_CR24","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1016\/j.cmi.2016.03.010","volume":"22","author":"MJT Crobach","year":"2016","unstructured":"Crobach MJT, Planche T, Eckert C, Barbut F, Terveer EM, Dekkers OM, et al. ESCMID update of the diagnostic guidance for clostridium difficile infection. Clin Microbiol Infect. 2016;22(Suppl 4):S63\u201381.","journal-title":"Clin Microbiol Infect"},{"key":"1859_CR25","doi-asserted-by":"crossref","unstructured":"Tenover FC, Novak-Weekley S, Woods CW, Peterson LR, Davis T, Schreckenberger P et al. Impact of strain type on detection of toxigenic Clostridium difficile. J Clin Microbiol. 2010;48(10):3719\u201324. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC2953097\/. [cited 2025 Dec 7].","DOI":"10.1128\/JCM.00427-10"},{"key":"1859_CR26","unstructured":"European Centre for Disease Prevention and Control. European surveillance of Clostridioides difficile infections: protocol v2.4. Luxembourg: Publications Office of the EU. 2019. Available from: https:\/\/data.europa.eu\/doi\/10.2900\/60304. [cited 2025 May 18]."},{"key":"1859_CR27","volume-title":"Salud P\u00fablica y Gesti\u00f3n Sanitaria. EPINE-EPPS 2024","author":"Sociedad Espa\u00f1ola de Medicina Preventiva","year":"2024","unstructured":"Sociedad Espa\u00f1ola de Medicina Preventiva. Salud P\u00fablica y Gesti\u00f3n Sanitaria. EPINE-EPPS 2024. Madrid: EPINE; 2024."},{"issue":"9","key":"1859_CR28","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1017\/ice.2024.125","volume":"45","author":"JH Kwon","year":"2024","unstructured":"Kwon JH, Advani SD, Branch-Elliman W, Braun BI, Cheng VCC, Chiotos K, et al. SHEA research agenda to combat healthcare-associated infections. Infect Control Hosp Epidemiol. 2024;45(9):1023\u201340.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"1","key":"1859_CR29","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1017\/ash.2023.148","volume":"3","author":"P Cornejo-Ju\u00e1rez","year":"2023","unstructured":"Cornejo-Ju\u00e1rez P, Volkow-Fern\u00e1ndez P, V\u00e1zquez-Mar\u00edn CL, \u00c1lvarez-Romero N, Garc\u00eda-Pineda B, Chavez-Chavez T, et al. Impact of COVID-19 on nosocomial infections in an oncology hospital. Antimicrob Steward Healthc Epidemiol. 2023;3(1):e70.","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"1859_CR30","doi-asserted-by":"publisher","first-page":"102579","DOI":"10.1016\/j.anaerobe.2022.102579","volume":"75","author":"N Merchante","year":"2022","unstructured":"Merchante N, Chico P, M\u00e1rquez-Saavedra E, Riera G, Herrero R, Gonz\u00e1lez-de-la-Aleja P, et al. Impact of COVID-19 pandemic on healthcare-associated Clostridioides difficile infection. Anaerobe. 2022;75:102579.","journal-title":"Anaerobe"},{"key":"1859_CR31","doi-asserted-by":"publisher","unstructured":"Weiner-Lastinger LM, Pattabiraman V, Konnor RY, et al. Impact of COVID-19 on healthcare-associated infections in 2020. Infection Control & Hospital Epidemiology. 2022; 43: 12\u201325. https:\/\/doi.org\/10.1017\/ice.2021.362.","DOI":"10.1017\/ice.2021.362"},{"issue":"5","key":"1859_CR32","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.3892\/etm.2021.10649","volume":"22","author":"S Sipos","year":"2021","unstructured":"Sipos S, Vlad C, Prejbeanu R, Haragus H, Vlad D, Cristian H, et al. Impact of COVID-19 prevention measures on C. difficile infections. Exp Ther Med. 2021;22(5):1215.","journal-title":"Exp Ther Med"},{"key":"1859_CR33","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231165581","volume":"16","author":"SP Bachour","year":"2023","unstructured":"Bachour SP, Dalal R, Allegretti JR. Effect of COVID-19 on Clostridioides difficile and fecal microbiota transplantation. Ther Adv Gastroenterol. 2023;16:17562848231165581.","journal-title":"Ther Adv Gastroenterol"},{"key":"1859_CR34","doi-asserted-by":"publisher","first-page":"102484","DOI":"10.1016\/j.anaerobe.2021.102484","volume":"74","author":"G Granata","year":"2022","unstructured":"Granata G, Petrosillo N, Al Moghazi S, Caraffa E, Puro V, Tillotson G, et al. Burden of C. difficile in COVID-19 patients: systematic review. Anaerobe. 2022;74:102484.","journal-title":"Anaerobe"},{"issue":"1","key":"1859_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ajic.2020.10.002","volume":"49","author":"ML Martinez-Fierro","year":"2021","unstructured":"Martinez-Fierro ML, R\u00edos-Jasso J, Garza-Veloz I, Reyes-Veyna L, Cerda-Luna RM, Duque-Jara I, et al. Close contacts and COVID-19 transmission in Mexico. Am J Infect Control. 2021;49(1):15\u201320.","journal-title":"Am J Infect Control"},{"issue":"12","key":"1859_CR36","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1080\/14740338.2023.2234821","volume":"22","author":"M Lucijanic","year":"2023","unstructured":"Lucijanic M, Busic N, Stojic J, Barisic-Jaman M, Zagorec N, Lazibat K, et al. PPI use prior to COVID-19 hospitalization increases C. difficile risk. Expert Opin Drug Saf. 2023;22(12):1265\u201370.","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"1859_CR37","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1111\/jonm.13383","volume":"29","author":"LJ Labrague","year":"2021","unstructured":"Labrague LJ. Pandemic fatigue and nurses\u2019 mental health during COVID-19. J Nurs Manag. 2021;29(7):1992\u20132001.","journal-title":"J Nurs Manag"},{"issue":"9","key":"1859_CR38","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa1408913","volume":"372","author":"FC Lessa","year":"2015","unstructured":"Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden of C. difficile infection in the US. N Engl J Med. 2015;372(9):825\u201334.","journal-title":"N Engl J Med"},{"key":"1859_CR39","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.2147\/CIA.S149089","volume":"12","author":"T Asempa","year":"2017","unstructured":"Asempa T, Nicolau D. C. difficile infection in the elderly: update. Clin Interv Aging. 2017;12:1799\u2013809.","journal-title":"Clin Interv Aging"},{"key":"1859_CR40","unstructured":"World Health Organization. Overuse of antibiotics in hospitalized COVID-19 patients. 2024. Available from: https:\/\/www.who.int\/news\/item\/26-04-2024-who-reports-widespread-overuse-of-antibiotics-in-patients--hospitalized-with-covid-19. [cited 2025 May 19]."},{"issue":"2","key":"1859_CR41","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40121-024-00922-5","volume":"13","author":"CH Huang","year":"2024","unstructured":"Huang CH, Tseng YH, Tsai WS, Su CC, Cheng CL, Kao Yang YH, et al. PPI\/H2RA duration and risk of C. difficileinfection. Infect Dis Ther. 2024;13(2):373\u201383.","journal-title":"Infect Dis Ther"},{"issue":"9","key":"1859_CR42","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1001\/archinternmed.2010.89","volume":"170","author":"MD Howell","year":"2010","unstructured":"Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and risk of C. difficile. Arch Intern Med. 2010;170(9):784\u201390.","journal-title":"Arch Intern Med"},{"issue":"7","key":"1859_CR43","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.mayocp.2011.12.021","volume":"87","author":"S Khanna","year":"2012","unstructured":"Khanna S, Aronson SL, Kammer PP, Baddour LM, Pardi DS. Gastric acid suppression and outcomes in C. difficile. Mayo Clin Proc. 2012;87(7):636\u201342.","journal-title":"Mayo Clin Proc"},{"key":"1859_CR44","unstructured":"Gherlan GS, Florescu SA, Enyedi M, Efrem IC, Mitrea A, Clenciu D et al. Three-year mortality analysis in C. difficilepatients. Cureus. 2024."},{"issue":"1","key":"1859_CR45","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12879-023-08096-0","volume":"23","author":"P Feuerstadt","year":"2023","unstructured":"Feuerstadt P, Theriault N, Tillotson G. Burden of CDI in the US: multifactorial challenge. BMC Infect Dis. 2023;23(1):132.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"1859_CR46","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3390\/antibiotics13040367","volume":"13","author":"M Stoian","year":"2024","unstructured":"Stoian M, Andone A, Boeriu A, B\u00e2ndil\u0103 SR, Dobru D, Laszlo S, \u0218tefan, et al. COVID-19 and C. difficile coinfection in ICU. Antibiotics. 2024;13(4):367.","journal-title":"Antibiotics"},{"key":"1859_CR47","doi-asserted-by":"publisher","unstructured":"Bhattacharjee R, Pulungan Z, Tiegland C. Trends in readmissions and mortality in Clostridioides difficile infection. Online Journal of Public Health Informatics. 2014;6(1):e188. https:\/\/doi.org\/10.5210\/ojphi.v6i1.5162.","DOI":"10.5210\/ojphi.v6i1.5162"},{"key":"1859_CR48","doi-asserted-by":"crossref","unstructured":"Czepiel J, Krutova M, Mizrahi A, Khanafer N, Enoch DA, Patyi M, et al. Mortality after Clostridioides difficileinfection in Europe. Antibiotics. 2021;10(3):299.","DOI":"10.3390\/antibiotics10030299"},{"issue":"2","key":"1859_CR49","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40121-024-00919-0","volume":"13","author":"J Eeuwijk","year":"2024","unstructured":"Eeuwijk J, Ferreira G, Yarzabal JP, Robert-Du Ry Van Beest Holle M. Systematic review on risk factors and timing of C. difficile infection in the US. Infect Dis Ther. 2024;13(2):273\u201398.","journal-title":"Infect Dis Ther"},{"issue":"4","key":"1859_CR50","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3892\/etm.2021.10546","volume":"22","author":"DN P\u0103duraru","year":"2021","unstructured":"P\u0103duraru DN, Ion D, Dumitra\u0219cu M, Petca R, Petca A, \u0218andru F, et al. Characteristics of C. difficile infection in a surgery clinic. Exp Ther Med. 2021;22(4):1112.","journal-title":"Exp Ther Med"},{"key":"1859_CR51","unstructured":"Xunta de Galicia. Resoluci\u00f3n 7\/2019 sobre protocolo de tratamiento de datos complementarios en historias cl\u00ednicas. DOG N\u00ba 17. 2020. Available from: https:\/\/www.xunta.gal\/dog\/Publicados\/2020\/20200127\/AnuncioC3K1-170120-0001_es.html. [cited 2025 Jun 28]."}],"container-title":["Archives of Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13690-026-01859-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13690-026-01859-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13690-026-01859-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:44:57Z","timestamp":1774615497000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13690-026-01859-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1859"],"URL":"https:\/\/doi.org\/10.1186\/s13690-026-01859-6","relation":{},"ISSN":["2049-3258"],"issn-type":[{"value":"2049-3258","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"28 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted as a healthcare quality assessment project (clinical audit) rather than biomedical research, and therefore did not require approval from a Research Ethics Committee, in accordance with the\n                      Guide for Members of Research Ethics Committees\n                      by the Council of Europe\u00b4s Steering Committee on Bioethics, and regional policy (Resolution of January 15, 2020, Instruction 7\/2019 from the Galician Department of Health) [\n                      \n                      ].According to the aforementioned Guide, clinical audits \u2014 defined as reviews carried out within healthcare institutions to \u201cdetermine whether best practices have been adopted\u201d \u2014 are not subject to prior evaluation by a Research Ethics Committee. In Galicia, Instruction 7\/2019 regulates quality assessments aimed at evaluating clinical protocols to determine whether adjustments or improvements are necessary. These assessments must be authorized by the director of the healthcare institution. The study protocol was approved on August 24, 2022.The research adhered to the ethical principles outlined in the D\n                      eclaration of Helsinki of the World Medical Association\n                      (1964) and the\n                      Convention on Human Rights and Biomedicine\n                      , signed in Oviedo on April 4, 1997. It also complied with applicable European, national, and regional regulations concerning health, research, and personal data protection.Clinical data were pseudonymized and extracted from the database of the Preventive Medicine Service of the\n                      Xerencia de Xesti\u00f3n Integrada A Coru\u00f1a\n                      . Anonymity and confidentiality of all individuals were fully preserved.This study is reported in accordance with the\n                      STROBE\n                      (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}